Sense Biodetection secures £35.9m Series B funding from Koch Disruptive Technologies to launch rapid COVID-19 test
Koch Disruptive Technologies led the Series B round to support the commercialisation of the Veros diagnostics platform.
Sense Biodetection is a global molecular diagnostics company that develops instrument free rapid molecular tests to improve healthcare access. The firm is preparing to launch its Veros platform, starting with a COVID-19 test.
Sense Biodetection has secured £35.9m in a Series B funding round led by Koch Disruptive Technologies. The capital will be deployed to advance the commercialisation of the company's Veros COVID-19 product and expand its portfolio of rapid molecular tests. Additional backing for the round came from existing investors including Cambridge Innovation Capital, Earlybird Health, Jonathan Milner, and Mercia Asset Management.
The Oxford-based diagnostics company aims to scale its manufacturing capabilities to bring laboratory-quality testing directly to users without the need for instruments. This funding supports the firm's broader objective to decentralise healthcare delivery and improve patient outcomes through accessible diagnostic tools.
From the founder
"This Series B round is crucial in providing us with the resources to grow our Veros platform to revolutionize decentralized point-of-care testing; and it is particularly important as we commercialize our Veros COVID-19 test, which delivers laboratory quality results directly to users within minutes, without an instrument. This will be an essential tool in the effective management of outbreaks of this and other diseases,"
Harry Lamble
CEO at Sense Biodetection
Investor perspective
"KDT sees huge potential for Sense’s Veros platform to transform the way medical providers and patients approach healthcare, empowering more choice, increased access, and better quality of care. Sense’s vision to decentralize the healthcare system, through its flexible point-of-care testing capabilities for a variety of diseases, presents a foundational shift in an industry ripe for disruption,"
Chase Koch
President, Koch Disruptive Technologies
Investors
Chase Koch
Koch Disruptive Technologies
Cambridge Innovation Capital
Earlybird Health
Jonathan Milner
Mercia Asset Management
Categories
About the company
Sense Biodetection
Sense Biodetection develops rapid molecular diagnostic tests for decentralized healthcare.